Who
Jan Skvarka
Director
Company insider
Files Form 4 as: Director, Zentalis Pharmaceuticals; Director, Monte Rosa Therapeutics; President and CEO, Trillium Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 1
- Sells
- 5
- Bought
- $103K
- Sold
- $1.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 13 Jan 2021
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,603 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $103K60,000 at $1.72 | filing |
| 21 Jun 2024filed 21 Jun 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —41,581 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 11 Sep 2023filed 13 Sep 2023 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $125K5,000 at $25.05 | filing |
| 16 Jun 2023filed 16 Jun 2023 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,364 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,500 at $0.00 | filing |
| 30 Mar 2023filed 31 Mar 2023 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 9 Sep 2022filed 12 Sep 2022 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —36,606 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —197,000 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,162,500 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —600,000 at $0.00 | filing |
| 12 May 2021filed 13 May 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code M | —23,802 at $0.00 | filing |
| 12 May 2021filed 13 May 2021 | Trillium Therapeutics | SEC FORM 4 Code M | $7,37923,802 at $0.31 | filing |
| 12 May 2021filed 13 May 2021 | Trillium Therapeutics | SEC FORM 4 Sold | $220K23,802 at $9.24 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Jan Skvarka; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.